Loss of GATA6 was found in 55/82 (67%) of serous carcinomas, 1/12 (8.3%) of mucinous carcinomas, 10/12 (83%) of clear cell carcinoma, and 5/5 (100%) of endometroid carcinomas. Here, GATA6 is linked to serous adenocarcinoma.